

# TYK2 kinase inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/T704EE98304CEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: T704EE98304CEN

## Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "TYK2 Kinase Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 Kinase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### TYK2 Kinase Inhibitors Understanding

#### TYK2 Kinase Inhibitors: Overview

Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene. Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family. This protein associates with the cytoplasmic domain of type I and type II cytokine receptors and promulgate cytokine signals by phosphorylating receptor subunits. It is also component of both the type I and type III interferon signaling pathways. Selective inhibition of Tyk2 can provide pharmacological benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TYK2 Kinase Inhibitors R&D. The therapies under development are focused on novel approaches for TYK2 Kinase Inhibitors.

## TYK2 Kinase Inhibitors Emerging Drugs Chapters

This segment of the TYK2 Kinase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## TYK2 Kinase Inhibitors Emerging Drugs

### Deucravacitinib: Bristol-Myers Squibb

Deucravacitinib (formerly BMS 986165) is an orally available, selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease. Bristol Myers Squibb is evaluating deucravacitinib in Phase 3 clinical studies in psoriasis.

### Brepocitinib: Pfizer

Brepocitinib (PF-06700841) is a selective topical, tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1) inhibitor. The drug is in phase 2 clinical studies for the potential treatment of psoriasis and Atopic dermatitis in topical formulation and, in oral formulation for psoriatic arthritis, Crohn's disease, Ulcerative colitis, vitiligo, systemic lupus erythematosus, Alopecia areata and hidradenitis suppurativa.

Further product details are provided in the report.....

## TYK2 Kinase Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different TYK2 Kinase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players working on TYK2 Kinase Inhibitors

There are approx. 15+ key companies which are developing the TYK2 Kinase Inhibitors. The companies which have their TYK2 Kinase Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.

### Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

TYK2 Kinase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TYK2 Kinase Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TYK2 Kinase Inhibitors therapeutic

drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TYK2 Kinase Inhibitors drugs.

### TYK2 Kinase Inhibitors Report Insights

TYK2 Kinase Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### TYK2 Kinase Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

### Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing TYK2 Kinase Inhibitors drugs?

How many TYK2 Kinase Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for TYK2 Kinase Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TYK2 Kinase Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for TYK2 Kinase Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Incyte Corporation

Bristol-Myers Squibb

Oncostellae

Pfizer

Galapagos

Haisco Pharmaceutical Group

Sareum

Oncostellae

## Key Products

Baricitinib

Deucravacitinib

OST-122

Brepocitinib

GLPG-3121

FTP 637

SDC-1801

OST-246

## Contents

Introduction

Executive Summary

TYK2 Kinase Inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

TYK2 Kinase Inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

TYK2 Kinase Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value

Trends

TYK2 Kinase Inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Deucravacitinib: Bristol-Myers Squibb

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Brepocitinib: Pfizer

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

GLPG-3121 Galapagos

Product Description



Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Pre-clinical and Discovery Stage Products  
Comparative Analysis  
FTP 637: Haisco Pharmaceutical Group  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
Comparative Analysis  
TYK2 Kinase Inhibitors Key Companies  
TYK2 Kinase Inhibitors Key Products  
TYK2 Kinase Inhibitors- Unmet Needs  
TYK2 Kinase Inhibitors- Market Drivers and Barriers  
TYK2 Kinase Inhibitors- Future Perspectives and Conclusion  
TYK2 Kinase Inhibitors Analyst Views  
TYK2 Kinase Inhibitors Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for TYK2 Kinase Inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for TYK2 Kinase Inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: TYK2 kinase inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/T704EE98304CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T704EE98304CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970